Tempest Therapeutics (NASDAQ:TPST) Issues Earnings Results

Tempest Therapeutics (NASDAQ:TPST) posted its quarterly earnings results on Thursday. The company reported ($2.53) EPS for the quarter, missing analysts’ consensus estimates of ($0.28) by ($2.25), FiscalAI reports.

Tempest Therapeutics Price Performance

Shares of Tempest Therapeutics stock traded up $0.25 during trading hours on Thursday, hitting $2.09. 252,668 shares of the company’s stock traded hands, compared to its average volume of 176,203. Tempest Therapeutics has a 12-month low of $1.50 and a 12-month high of $12.23. The stock has a market capitalization of $29.98 million, a price-to-earnings ratio of -0.31 and a beta of -1.75. The company has a fifty day simple moving average of $1.96 and a 200-day simple moving average of $3.42.

Insider Activity at Tempest Therapeutics

In other Tempest Therapeutics news, CEO Matthew Angel purchased 231,482 shares of the stock in a transaction dated Tuesday, March 24th. The shares were bought at an average price of $2.16 per share, with a total value of $500,001.12. Following the completion of the transaction, the chief executive officer directly owned 231,482 shares in the company, valued at approximately $500,001.12. This trade represents a ? increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. 6.28% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Tempest Therapeutics

An institutional investor recently raised its position in Tempest Therapeutics stock. Vanguard Group Inc. increased its position in Tempest Therapeutics, Inc. (NASDAQ:TPST) by 20.8% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 162,560 shares of the company’s stock after acquiring an additional 27,952 shares during the quarter. Vanguard Group Inc. owned about 3.66% of Tempest Therapeutics worth $1,671,000 at the end of the most recent quarter. 22.52% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

TPST has been the subject of a number of research reports. Zacks Research upgraded shares of Tempest Therapeutics from a “hold” rating to a “strong-buy” rating in a report on Thursday, April 2nd. Wall Street Zen upgraded Tempest Therapeutics to a “hold” rating in a report on Saturday, April 18th. One analyst has rated the stock with a Strong Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy”.

Tempest Therapeutics Company Profile

Tempest Therapeutics is a clinical?stage biopharmaceutical company focused on the discovery and development of small molecule therapies for cancer and immune?mediated diseases. Leveraging a proprietary drug discovery platform, Tempest advances programs designed to modulate tumor metabolism and enhance antitumor immunity. Its pipeline includes oral, selective inhibitors targeting pathways such as peroxisome proliferator?activated receptor alpha (PPAR?) and salt?inducible kinase (SIK), with potential applications across solid tumors and hematologic malignancies.

The company’s lead candidate, TPST-1120, is a first?in?class PPAR? antagonist designed to reprogram the tumor microenvironment by disrupting fatty acid oxidation in immune and cancer cells.